Clinical data | |
---|---|
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a682022 |
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 3–9 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.001.514 |
Chemical and physical data | |
Formula | C11H12N2O2 |
Molar mass | 204.229 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ethotoin (previously marketed as Peganone) is an anticonvulsant drug used in the treatment of epilepsy. It is a hydantoin, similar to phenytoin. It is not available in the United States.
Similar to phenytoin.
Ethotoin is indicated for tonic-clonic and partial complex seizures.
Ethotoin is available in 250 mg tablets. It is taken orally in 4 to 6 divided doses per day, preferably after food.
Ataxia, visual disturbances, rash and gastrointestinal problems.
Ethotoin, 3-ethyl-5-phenylimidazolidine-2,4-dione, is synthesized by the reaction of benzaldehyde oxynitrile, with urea or ammonium hydrocarbonate, which forms an intermediate urea derivative which on acidic conditions cyclizes to 5-phenylhydantoin. Alkylation of this product using ethyliodide leads to the formation of ethotoin.